{ Banner Image }

Honigman represents Sunshine Heart, Inc. in its public offering of common shares on Nasdaq

September 24, 2013


Susan Sherbow
T: 313.465.7048

Honigman Miller Schwartz and Cohn LLP represented Sunshine Heart, Inc. (Nasdaq: SSH), a Minneapolis-based global medical technology company, in its public offering of 3,810,000 shares of its common stock with a 30-day option for the underwriters to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any.  The offering closed today.

Phillip D. Torrence, a partner in the firm’s Corporate Department and leader of its Corporate and Securities and Financial Institutions Practice Groups, was the lead attorney advising on this offering. He was assisted by Honigman attorneys Melanie Van Antwerp, Justin Crawford and Jeff Kuras.

“Honigman’s guidance has been invaluable to Sunshine Heart, Inc. during this monumental milestone in our history,” said Dave Rosa, Sunshine Heart’s CEO and President.  “This offering provides us with funds to further advance our pivotal trial and post-market EU study and our initial commercialization activities.”

Piper Jaffray & Co. and Cowen and Company, LLC acted as joint book-running managers and Lazard Capital Markets LLC acted as co-lead manager for the offering. Craig-Hallum Capital Group and Northland Securities, Inc. acted as co-managers for the offering. 

About Sunshine® Heart

Sunshine Heart, Inc. (Nasdaq: SSH) is a medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure.  Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in November 2011.  In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application.  Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal trial.  In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse System in Europe.  Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia.  The Company has been listed on the NASDAQ Capital Market since February 2012.